Lantheus/$LNTH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Primary listing
Employees
808
Headquarters
Website
Lantheus Metrics
BasicAdvanced
$3.9B
15.17
$3.77
0.09
-
Price and volume
Market cap
$3.9B
Beta
0.09
52-week high
$111.29
52-week low
$47.25
Average daily volume
1.4M
Financial strength
Current ratio
4.29
Quick ratio
3.685
Long term debt to equity
52.683
Total debt to equity
52.751
Interest coverage (TTM)
22.00%
Profitability
EBITDA (TTM)
494.005
Gross margin (TTM)
63.75%
Net profit margin (TTM)
17.82%
Operating margin (TTM)
28.46%
Effective tax rate (TTM)
28.00%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
13.34%
Return on equity (TTM)
24.71%
Valuation
Price to earnings (TTM)
15.17
Price to revenue (TTM)
2.596
Price to book
3.33
Price to tangible book (TTM)
6.18
Price to free cash flow (TTM)
9.261
Free cash flow yield (TTM)
10.80%
Free cash flow per share (TTM)
6.18
Growth
Revenue change (TTM)
5.75%
Earnings per share change (TTM)
-37.87%
3-year revenue growth (CAGR)
31.80%
10-year revenue growth (CAGR)
17.59%
3-year earnings per share growth (CAGR)
101.44%
10-year earnings per share growth (CAGR)
10.82%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Bulls say / Bears say
RTTNews reports that the FDA accepted Lantheus’ NDA for a new formulation of its PSMA PET imaging agent designed to expand batch size by about 50%, which should improve patient access and strengthen supply reliability (RTTNews).
In July, Lantheus closed its acquisition of Life Molecular Imaging, immediately gaining Neuraceq® for Alzheimer’s diagnostics and broadening its radiodiagnostic offerings, supporting long-term growth prospects (Comtex).
The board approved a $400 million share repurchase program, reflecting management’s confidence in sustained value creation and the company’s financial position (Comtex).
Lantheus’ Q2 2025 revenue dropped 4.1% year-over-year to $378.0 million, leading the company to lower its full-year revenue guidance by about 5% and cut adjusted EPS guidance by around 17%, highlighting execution issues in its main business (Investing.com).
Intense competition in the PSMA PET imaging market is pressuring PYLARIFY pricing and posing challenges to maintaining growth in Lantheus’ key oncology diagnostics segment (Investing.com).
B. Riley lowered its Q3 2025 EPS estimate for Lantheus from $1.36 to $1.02, signaling analysts’ doubts regarding near-term profitability and operational prospects (American Market News).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
LANTHEUS DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Newsfile Corp12 hours ago
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Lantheus
Business Wire22 hours ago
LANTHEUS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Newsfile Corp1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $3.9B as of November 07, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 15.17 as of November 07, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.